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INTRODUCTION 
 Tuberculosis remains a major global health problem, despite the 
identification of the causative agent 135 years ago and the advent of effective 
anti-tuberculosis therapy1. This is attributable to many factors like emergence 
of virulent strains, multi drug resistance, and rise of HIV pandemic among 
others2. In India, tuberculosis remains one of the leading causes of mortality 
and morbidity3. 
 Mycobacterium tuberculosis, the causative agent of tuberculosis is an 
intracellular microbe, capable of evading the host immune system and 
persisting within the macrophages even in the face of host immune response4. 
Granuloma formation with or without caseation necrosis, the hallmark of 
tuberculosis is a delayed type hypersensitivity or Type IV hypersensitivity 
reaction5. Granulomas, however are not limited to tuberculous infections, but 
can also occur in variety of settings like Leprosy, Atypical Mycobacterial 
Infections, Schistosomiasis, Histoplasmosis, Cryptococcosis and Cat Scratch 
Disease, and in non-infectious conditions like Crohn’s Disease, Sarcoidosis, 
Primary Biliary Cirrhosis, Rheumatoid Arthritis, Foreign Body Granulomas 
and even in Neoplasms6,7,8,9. Thus a definitive diagnosis needs to be made in 
the setting of granulomas, because in developing countries where there is 
dearth of availability of resources, treatment of tuberculosis has largely been 
modelled on presumptive diagnosis based on the imaging findings and clinical 
symptoms, which carries a high false positive rate10. 
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 Although few classification systems exist for tuberculosis, it has been 
conventionally classified as Pulmonary Tuberculosis (PTB) and Extra 
Pulmonary Tuberculosis (EPTB), based on which treatment strategies also 
differ11.  
 Diagnosis of pulmonary tuberculosis had always relied on sputum 
microscopy, acid fast staining of the bacilli and culture until the advent of 
molecular diagnostic tests like polymerase chain reaction (PCR), Xpert 
MTB/RIF (Nested PCR), although the definitive diagnosis of TB requires 
culture of Mycobacterium from respiratory secretions with sensitivity testing12. 
Culture, however takes several weeks, before a result is obtained13. World 
Health Organisation recommends the use of Xpert MTB/RIF as the initial 
diagnostic test to diagnose PTB, based on systematic reviews14. The efficacy of 
Xpert MTB/RIF in diagnosing PTB in sputum positive, culture positive cases, 
as well as in sputum negative, culture positive cases has been well 
documented15,16.  
Unlike PTB, where sputum samples and even Broncho alveolar lavage 
are easily obtained and sent for analysis, sample collection in EPTB is always 
invasive17,18. WHO policy update in 2013 recommended that Xpert MTB/RIF 
be used as initial diagnostic test in EPTB as well based on the review of 
published studies19,20,21. Although Xpert MTB/RIF has proved its efficacy and 
reliability as an initial rapid diagnostic test in EPTB, it is expensive and 
sensitive to contamination22. Such tests are still out of reach for patients owing 
to the cost factor in developing countries23.  
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ROLE OF HISTOPATHOLOGY:  
 Histopathology of formalin fixed paraffin embedded tissue sections can 
provide a presumptive diagnosis of tuberculosis based on the morphology of 
granulomas and the presence of caseation necrosis & Langhans giant cells, 
although non-necrotizing granulomas also occur24,25. However as mentioned 
earlier, it cannot reliably distinguish from other causes of granulomas6,7,8,9. This 
can result in under-treatment and sometimes in erroneous over-treatment26. 
ROLE OF SPECIAL STAINS: 
 Mycobacterium tuberculosis is acid fast, meaning that they resist 
decolourization by acids, which can be utilized for their identification by 
special stains27. Some of the stains which can be used include but not limited to 
Ziehl-Neelsen stain, Kinyoun stain and fluorochrome based stains like 
auramine-rhodamine stain, of which Ziehl-Neelsen stain is the most widely 
used28. The tubercle bacilli appear as red curved rods which can be easily 
identified against the blue background29. Ziehl-Neelsen stain, although is rapid 
and inexpensive has very low and variable sensitivity which depends on the 
bacterial load30. 
ROLE OF IMMUNOHISTOCHEMISTRY (IHC): 
 IHC can localize the bacilli or their components in the tissue sections, 
for which both monoclonal and polyclonal antibodies are available31,32. IHC 
offers a significant advantage over Ziehl-Neelsen in that, it can detect tubercle 
bacilli even when there is low bacterial load and even in those who were 
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partially treated33. In areas where Xpert MTB/RIF is not available or not 
affordable by the patients, IHC could be an effective alternative which could 
reduce the time to treatment33,34. 
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AIMS AND OBJECTIVES 
1. To evaluate the diagnostic value of immunohistochemical analysis using 
rabbit polyclonal mycobacterium tuberculosis antibody in suspected 
tuberculous lesions 
2. To compare the immunohistochemical analysis with Ziehl-Neelsen (ZN) 
staining in tissue sections of suspected tuberculous lesions 
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REVIEW OF LITERATURE 
INTRODUCTION:  
Tuberculosis is a highly infectious disease caused by the bacterium 
Mycobacterium tuberculosis35. It is primarily an infection of the lungs 
(pulmonary tuberculosis), though it can affect virtually any organ system 
including but not limited to lymph nodes, gastrointestinal tract, genitourinary 
tract, bone & joints, meninges and skin (extra pulmonary tuberculosis)36,37.  
HISTORICAL PERSPECTIVE:  
The name tuberculosis derives its origin from the Latin word tuberculum 
meaning "small swelling or pimple”, so named in reference to the tubercles 
found in the lungs38. Tuberculosis has been referred to by a multitude of names 
over time, which include white plague, consumption, Pott’s disease & 
phthisis39,40,41. Tuberculosis has plagued mankind for much of known history, 
though the exact origin is debatable42.  
Gutierrex et al via DNA sequencing and phylogenetic analyses, 
estimated that the progenitor species of mycobacterium tuberculosis may be 3 
million years old and may have infected our hominid ancestors43. The earliest 
documentation of tuberculosis dates back to circa 3500 B.C. inferred from the 
Egyptian tomb paintings and examination of mummies which showed 
tubercular lesions44. In ancient India, dating back to circa 1500 B.C., the Rig 
Veda describes a disease, ‘Yaksma’ which translates to ‘wasting disease’, 
closely resembling that of tuberculosis45.  
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For millennia, the aetiology of tuberculosis remained unknown. But in 
1882, Robert Heinrich Hermann Koch identified the causative agent of 
tuberculosis as tubercle bacillus, later came to be known as Mycobacterium 
tuberculosis46. Koch also demonstrated the tuberculin reaction, which later 
formed the basis for Mantoux test47. The identification of the offending agent 
was followed by the development of Bacillus Calmette-Guerin vaccine and the 
discovery of streptomycin and other anti-tubercular drugs48. Despite the 
advancement, tuberculosis remains unconquered and is one of the leading 
infectious causes of mortality & morbidity49. 
EPIDEMIOLOGY:  
Tuberculosis has become an epidemic of vast proportion, so much so 
that World Health Organization (WHO) declared it as a global emergency in 
199350. According to WHO, it has been estimated that 2-3 billion of the 
world’s population have been infected with M.tuberculosis and about 5%-15% 
of them will develop tuberculosis in their lifetime51.  
India has the highest tuberculosis burden in the world accounting for 
27% of global incident tuberculosis cases51. The estimated incidence of 
tuberculosis in India for the year 2015 was 28, 40,000. Among the notified 
cases, 82% were pulmonary tuberculosis and 18% were extra pulmonary 
tuberculosis. The mortality rate was 36 per 100,000 population52.  
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RISK FACTORS:  
An untreated sputum positive patient can infect approximately 10 
persons per year53. Hence close contacts of infectious TB cases are at a higher 
risk for acquiring infection and developing active disease. The risk of 
developing active disease after exposure is governed by a multitude of 
factors54.  
 Factors like HIV co-infection, malnutrition, younger age, diabetes, 
immunosuppressive drugs, tobacco smoke, silicosis, alcohol, air pollution, and 
low socioeconomic status play a significant role in the progression to active 
disease54,55,56,57. Specific groups such as health care workers are also at an 
increased risk of TB infection and disease58. 
ETIOLOGICAL AGENT:  
Tuberculosis is caused by the bacillus Mycobacterium tuberculosis. 
Mycobacterium are aerobic, non-sporing, non-motile rods59. Mycobacteria 
possess two types of antigens viz. cell wall antigens & cytoplasmic antigens60.  
The thick lipid rich cell envelope of mycobacteria is composed of three 
major constituents, the plasma membrane, the cell-wall core, and the 
extractable non-covalently linked glycans, lipids and proteins60. The major 
lipids in the mycobacterium tuberculosis cell wall are mycolic acids, cord 
factor, and wax-D61.  
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External to the plasma membrane is the peptidoglycan layer which is 
covalently linked to the arabinogalactan layer, which in turn is attached to the 
mycolic acids with their long meromycolate and shorter alkyl-chains62. This 
portion is termed the cell-wall core, the mycolyl arabinogalactan-peptidoglycan 
complex (MAPc)60,62.  
The mycolic acids unique to mycobacteria are long-chain fatty acids that 
are covalently bound to the arabinogalactan peptidoglycan co-polymer; they 
are implicated in the formation of the inner layer of an asymmetric outer 
membrane while other lipids constitute the outer leaflet63.   The mycolic acids 
extend perpendicular to the arabinogalactan / peptidoglycan while other cell 
wall-associated glycolipids intercalate into the mycolic acid layer to form a 
‘pseudo’ lipid bilayer60,62,63.  
When the cell wall is subjected to treatment with various solvents, the 
free lipids and proteins are solubilised and the MAPc remains as an insoluble 
residue. Thus it was hypothesised that these lipids, proteins, and lipoglycans 
which were soluble act as the signalling effector molecules in the disease 
process, whereas the insoluble MAPc core is necessary for the viability of the 
cell60. 
Cytoplasmic antigens are proteins which include antigen 5, antigen 6, 
antigen 14, antigen 19, antigen 32, and antigen 38. Antigen 60 is also a 
cytoplasmic antigen which is a protein lipopolysaccharide complex59.  
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Mycolic acids which are strongly hydrophobic form a lipid shell and are 
considered to be a significant determinant of virulence in Mycobacterium 
tuberculosis. They are thought to resist the attack of the mycobacteria by 
cationic proteins, lysozyme, and oxygen radicals in the macrophages64. They 
also protect extracellular mycobacteria from complement deposition in 
serum65. 
PATHOPHYSIOLOGY:  
 Tuberculosis is a highly communicable disease and the most important 
mode of transmission is by aerosol66. When patients with active tuberculosis 
cough, droplet nuclei of size 1–5 μm in diameter containing the bacteria are 
released into the air67. The relatively very small droplet nuclei can continue to 
persist in the air for several hours68.  
 The risk of infection is dependent on a multitude of factors like the 
infectiousness of the source case, the closeness of contact, the bacillary load 
inhaled, and the immune status of the potential host69. The primary path of 
infection affects the lungs and the droplet nuclei because of their relatively 
small size can escape the defence mechanisms of the bronchial tree and reach 
the terminal part of the alveoli where they get engulfed by the macrophages 
and dendritic cells70.  
          M. tuberculosis also infects cells other than phagocytic cells in the 
alveolar space such as the specialized epithelial M cells overlying the lymphoid 
tissue, alveolar endothelial cells, and type 1 & type 2 pneumocytes71.  
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 In the early stage of infection, M. tuberculosis after internalization by 
the phagocytes, replicates intracellularly and the bacteria laden immune cells 
can cross the alveolar barrier to cause systemic dissemination72. The 
intracellular replication of the pathogen and its subsequent dissemination to the 
pulmonary lymph nodes and other extra pulmonary sites occurs before the 
development of immune mediated adaptive responses73. This illustrates that M. 
tuberculosis carves for itself a protected niche, where it can evade the host 
immune system, thereby continuing to persist for an indefinite length of time74.  
In majority of the infected persons, the immune system mounts an effective T 
cell-mediated immune response 2–3 weeks after infection which then activate 
the macrophages to kill the intracellular mycobacteria75. The blood-derived 
macrophages, epithelioid cells (differentiated macrophages) and multinucleated 
giant cells (also known as Langhans giant cells) form granulomas surrounded 
by T lymphocytes, that wall off the bacteria limiting further replication and 
spread of the tubercle bacilli76.  
          Most of the M. tuberculosis are killed in the caseating granulomas, 
typical of the tuberculosis infection, which are formed by the epithelioid 
macrophages surrounding a cellular necrotic region with a rim of lymphocytes 
and the disease progression is arrested77. In some individuals, the tubercle 
bacilli is not completely eradicated, as the bacteria has developed effective 
mechanisms to escape the host immune response resulting in the survival and 
perseverance of some bacilli in a non-replicating state in the host78.  
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                Literature has showed that the tubercle bacilli has been cultured from 
lung tissue samples of persons who died from other causes and did not exhibit 
any signs & symptoms of tuberculosis, supporting the hypothesis of latent 
tuberculosis infection79. Surviving bacilli may remain dormant for a long time 
even lasting up to a lifetime, and a subsequent defect in cell-mediated 
immunity may result in reactivation of dormant bacilli causing active disease 
many years after the infection (reactivation TB)80. Hence exposure may lead to 
clearance of M. tuberculosis, persistent latent infection, or progression to 
primary disease81. 
IMMUNE REPSONSE – “THE GRANULOMATOUS 
INFLAMMATION”:  
 Granulomatous inflammation (delayed type hypersensitivity or Type IV 
hypersensitivity), the hallmark of tuberculosis, is rather an unsuccessful 
attempt to limit the infection, because it also provides a fertile 
microenvironment for the proliferation and survival of the tubercle bacilli, by 
modulating the immune response82. The balance between the pro-inflammatory 
cytokines and anti-inflammatory cytokines which are produced to control the 
microbial proliferation determines the establishment of infection83.  
 Cytokines like TNF-α and Interferon gamma promote the formation of 
granuloma whereas Interleukin-10 acts as a negative regulator84. The 
production of chemokines by the epithelial cells of the respiratory tract and the 
immune cells themselves, is also vital for the recruitment of inflammatory cells 
to the site of infection, particularly, the chemokines binding to the CCR2 
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receptor (CCL2/MCP-1, CCL12, and CCL13) which play an essential role for 
the early recruitment of macrophages85.  
           The tubercle bacilli are able to withstand the bactericidal mechanisms of 
the macrophage by inhibiting the fusion of phagosome and lysosome, multiply 
within the phagosome, ultimately resulting in macrophage necrosis86. The 
released bacilli also multiplies extracellularly and are then phagocytosed by 
another macrophage which also fails to control the growth of the tubercle 
bacilli and is similarly destroyed.  
 Meanwhile, dendritic cells with the phagocytosed bacilli migrate to the 
regional lymph nodes and sensitise the T lymphocytes (both CD4+ and CD8+) 
against the mycobacterial antigens87.The resulting specific immune response 
creates sensitised T cells which then transmigrate to the focus of infection, 
guided by the chemokines produced by the infected cells. The accumulation of 
the macrophages including the activated macrophages called the epithelioid 
cells, T lymphocytes, and other host cells like the dendritic cells, fibroblasts, 
endothelial cells, and stromal cells lead to the formation of granuloma at the 
site of infection88. 
PULMONARY TUBERCULOSIS:   
 Pulmonary tuberculosis accounts for about 85% of tuberculosis51.The 
classical initial site of infection in the lungs, known as the "Ghon focus", which 
is a sub pleural focus, is generally located in either the upper part of the lower 
lobe, or the lower part of the upper lobe, and together with the regional 
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draining lymph nodes constitute the “Ghon complex”, named after Anton 
Ghon, an Austrian pathologist89. This apical localisation of infection is 
attributed to several factors like low blood flow, low ventilation and high 
oxygen tension90.  
Haematogenous spread from a primary site of infection elsewhere in the 
body to lungs can result in a lesion which is known as a Simon focus, named 
after Georg Simon, a German paediatrician and is classically found in the apex 
of the lung91. This haematogenous transmission can also disseminate infection 
to more distant sites, like the peripheral lymph nodes, the kidneys, the brain, 
and the bones92. In many situations, the infection ebbs & tides with tissue 
destruction, necrosis which are often followed by healing and fibrosis93.  
Affected tissue is replaced by scarring or may result in the formation of 
cavities filled with caseous necrotic material. During the active phase of the 
disease, some of these cavities may be joined to the air passages like bronchi & 
bronchioles and this material can be coughed up which contains live tubercle 
bacilli, that can result in the spread of infection94. The clinical symptoms 
include productive cough, purulent sputum, haemoptysis, breathlessness, 
weight loss, anorexia, fever associated with night sweats, wasting and terminal 
cachexia95. 
EXTRA PULMONARY TUBERCULOSIS:  
 Extra pulmonary tuberculosis (EPTB), as the name implies, refers to the 
tuberculous infection of any organ except lungs (e.g., lymph nodes, pleura, 
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abdomen, genitourinary tract, skin, joints and bones, or central nervous system) 
96.It has been observed that EPTB constituted about 15 to 20 per cent of all 
cases of TB and its incidence has been on the rise in the past decade due to a 
multitude of factors97. The arrival of Human Immunodeficiency Virus (HIV) 
pandemic has made matters worse, with EPTB accounting for more than 50 per 
cent of all cases of tuberculosis in HIV positive individuals98.  
Lymph node tuberculosis:  
 Tuberculous lymphadenitis or as is known from ancient times as 
King’evil was believed to be cured by the Royal Touch up until the eighteenth 
century99. The Latin term ‘scrofula’ is also used to refer lymph node 
tuberculosis, which translates to ‘full-neck sow’ meaning the full appearance of 
fat around a pig’s neck100. Worldwide and in India, lymph node tuberculosis 
represents the most common form of EPTB101. Peripheral lymph nodes are 
most commonly affected and among the peripheral nodes, cervical group of 
lymph nodes frequently involved102.  
 Involvement of lymph node by tuberculosis is often the result of entry of 
pathogen through the tonsils or as a manifestation of systemic 
involvement103,104. The bacilli after gaining access to the respiratory tract, 
involves the hilar and mediastinal lymph nodes, which may occur as a primary 
infection or activation of a latent infection and may later disseminate via 
lymphatic system to involve peripheral nodes105. When the tonsil acts as a point 
of entry, the draining lymph nodes are affected and clinically presents with 
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enlarged neck nodes, which are discrete initially and then coalesce later to form 
matted nodes and break open due to the formation of pus106.  
 Thus tuberculous lymphadenopathy progresses through certain stages 
viz. mobile discrete nodes, matted nodes, abscess formation, pus discharge and 
sinus tract formation107. Tuberculous lymphadenitis commonly affects young 
adults and children108. Patients typically present with enlarging neck mass, 
fever with night sweats, loss of appetite, loss of weight and fatigue109. Patients 
with hilar and mediastinal lymphadenopathy typically present with cough and 
breathlessness110,111. Besides cervical and mediastinal lymph nodes, other less 
common group of nodes affected include axillary, mesenteric, perihepatic and 
inguinal lymphnodes112. Before the diagnosis of tuberculosis is arrived at, other 
causes of granulomas in lymph nodes must be excluded113. 
Pleural Tuberculosis:  
 Pleural tuberculosis is the second most common form of extra 
pulmonary tuberculosis and in spite of the proximity & intricate anatomic 
relationship to lung, it is considered as extra pulmonary form of tuberculosis114. 
It is one of the commonest causes of pleural effusion, affecting young adults 
with a male predominance115,116. It is hypothesized that a sub pleural tubercular 
focus rupturing into the pleural space, a few weeks after the primary infection, 
is behind the pathogenesis of tuberculous pleural effusion117.  
 The mycobacterial antigens elicit a delayed type hypersensitivity 
response, which leads to accumulation of fluid secondary to increased 
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permeability of pleural capillaries to serum proteins which caused increased 
oncotic pressure118. Other forms of presentation include empyema, 
calcification, pleural thickening, and pleural nodules119. Empyema is a rare 
manifestation of tuberculosis characterised by the presence of thick pus with 
thickening and calcification of the visceral pleura, for which decortication is 
often required120.  
 Increased incidence of pleural involvement in tuberculosis is seen in 
association with Acquired Immunodeficiency Syndrome (AIDS)121. The 
clinical manifestations include non-productive cough, chest pain, 
breathlessness, fever with night sweats, loss of weight, loss of appetite, and 
fatigue122. Rarely, pleural tuberculosis can present as a persistent chest wall 
mass or with chest wall sinus tract formation123, 124. 
Gastrointestinal & peritoneal tuberculosis:  
 Abdominal tuberculosis is the sixth most common form of extra 
pulmonary tuberculosis and can manifest as tuberculous lymphadenopathy, 
gastrointestinal tuberculosis, peritoneal tuberculosis and visceral 
tuberculosis125, 126. In the Gastrointestinal tract (GIT), tuberculosis can occur in 
any site from mouth to anus, with the most common site being ileocecal 
junction127, 128.  
 The reasons for increased incidence of tuberculosis in the terminal part 
of ileum include abundance of lymphoid tissue, increased stasis, increased 
absorptive activity and closer contact of tubercle bacilli with the mucosa129, 130. 
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The mechanisms by which the tubercle bacilli reach the GIT and cause 
infection include haematogenous spread, ingestion of infected sputum, 
contiguous spread from adjacent involved organs and through lymphatics131,132.  
 Oesophageal tuberculosis is a rare entity accounting for about 0.3% of 
GIT tuberculosis133. It usually involves the middle one third of the oesophagus 
and frequently presents with dysphagia134, 135. It usually occurs a part of 
systemic involvement and isolated involvement of oesophagus is extremely 
rare136. Gastroduodenal tuberculosis is also rare with reported incidence of 
around 0.5% of abdominal tuberculosis137. Symptoms are non-specific like 
pain, vomiting, dyspepsia and can mimic peptic ulcer or carcinomas138.  
 Duodenal tuberculosis can sometimes present with strictures and 
fistulas139. Ileocecal tuberculosis, the commonest form of GIT tuberculosis can 
present grossly as ulcerative, hypertrophic or a combination of both140. The 
symptoms include colicky or dull aching abdominal pain, altered bowel habits, 
vomiting, loss of weight and loss of appetite141.  
 Complications include strictures or adhesions, malabsorption and 
perforation128, 142. Grossly and microscopically, GIT tuberculosis needs to be 
distinguished from inflammatory bowel disease143. Colorectal tuberculosis can 
be multifocal in up to 40% of cases144. The most common finding is the 
presence of ulcers and can mimic Crohn’s disease145.  
 Peritoneal tuberculosis can present with any of the three forms viz. the 
wet ascitic type with increased amount of free fluid or loculated effusion, the 
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fixed fibrotic type with omental and mesenteric involvement with adherent 
bowel, the dry plastic type with peritoneal nodules and adhesions or as a 
combination of these146. The symptoms include abdominal distension, diffusely 
tender doughy abdomen with other classical symptoms of tuberculosis147. 
Hepatobiliary tuberculosis:  
 Hepatobiliary tuberculosis is rare and usually occurs in the setting of 
military tuberculosis148. The bacilli reach the hepatobiliary system by 
haematogenous route either via hepatic artery or portal vein149, 150. Tuberculosis 
of hepatobiliary system can occur in three forms viz. military tuberculosis 
which is the most common form, tuberculous hepatitis and localized hepatic 
tuberculosis with or without bile duct involvement151.  
 The clinical manifestations include hepatomegaly, fever, weight loss, 
abdominal pain, and jaundice152. Tuberculosis of gall bladder is extremely rare 
with less than 120 cases being reported in literature till date153. Most cases 
occur as part of disseminated tuberculosis154.  
Pancreatic tuberculosis:  
 Contrary to popular belief, tuberculosis can occur in pancreas and less 
than hundred cases have been reported in literature155. The rarity of the 
infection at this particular site has been attributed to the destructive nature of 
the pancreatic enzymes156. It occurs as part of disseminated tuberculosis and it 
is hypothesised that the infection is spread by haematogenous route157. The 
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clinical manifestations are non-specific and can mimic pancreatic 
adenocarcinoma158.  
Splenic tuberculosis:  
 Splenic tuberculosis can occur in two forms viz. either as part of 
military tuberculosis or primary isolated involvement of spleen159, 160. Spleen is 
the third most common organ to be involved in disseminated tuberculosis after 
lung and liver161. It has no specific symptoms and thus can be mistaken for a 
mass lesion, splenic abscess or lymphoma162. 
Neurological tuberculosis:  
 Neurological tuberculosis accounts for around 10% of extra pulmonary 
tuberculosis and 1% of all tuberculosis cases163. The pathogenesis involves the 
development of tuberculous foci called as ‘Rich Foci’ in any part of the central 
nervous system (CNS) viz. brain, spinal cord or meninges164. The disease can 
take the form of tuberculous meningitis which is the most common 
manifestation, or in the form of tuberculous encephalitis, intra cranial 
tuberculomas and tuberculous brain abscess164.  
 CNS involvement by tuberculosis is more common in HIV infected 
patients165. The release of tubercle bacilli into the subarachnoid space results in 
the formation of gelatinous exudate, which may extend and envelop the spinal 
cord, cranial arteries and cranial nerves, sometimes resulting in the obstruction 
of normal flow of cerebrospinal fluid causing hydrocephalus166.  
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 The dreaded complication of tuberculous meningitis includes the 
development of vasculitis of circle of Willis resulting in infarction166. 
Tuberculomas are small masses or tubercles ranging from few mm size to 4 
cm, which develop within the brain parenchyma without rupturing167. They 
account for about 10% of space occupying lesions in the brain and may or may 
not be associated with tuberculous meningitis167. Tuberculous brain abscess 
may be a complication of either tuberculous meningitis or tuberculomas, 
characterised by encapsulated collection of pus168.  
 Tuberculous meningitis presents with fever, headache, seizures, stiff 
neck, altered consciousness or focal neurological deficits169.  Tuberculomas or 
brain abscess elicit symptoms depending on their location which include fever, 
headache, seizures, signs of increased intracranial tension, and papilledema169. 
Tuberculomas can mimic neoplastic lesion clinically and radiologically and 
thus needs to be distinguished169. CSF analysis may reveal increased 
lymphocytes and increase in proteins and low sugar170.  
Pericardial tuberculosis:  
 Involvement of pericardium by tuberculosis can occur in the form of 
pericarditis, pericardial effusion and cardiac tamponade171. Tuberculosis is the 
leading cause of pericardial effusion, which has a very high mortality rate and 
occurs commonly in association with HIC infection37, 172. The involvement can 
progress through phases of dry stage, effusive stage, absorptive stage and 
constrictive stage37.  
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 Patients present with fever, cough, dyspnoea, chest pain, and weight loss 
and when presenting with tamponade, they can exhibit severe distress, 
retrosternal compression, tachycardia, cardiomegaly and pericardial rub which 
then becomes an emergency, necessitating the need for pericardiocentesis37. A 
definitive diagnosis is possible only by evaluation of pericardial fluid for 
tubercle bacilli or by biopsy37. 
Bone and joint tuberculosis:  
 Skeletal tuberculosis occurs due to haematogenous spread and spine is 
the most commonly affected part which is commonly known as Pott’s spine, 
followed by hip joint, knee joint, bones of hand & feet173. Thoracolumbar spine 
is the commonest site involved, with the disease process eventually causing 
bony destruction resulting in the collapse of vertebra173.  
 When involving the cervical vertebra, the exudate can track along the 
path of least resistance, and collect behind the prevertebral fascia and can 
present as retropharyngeal abscess, which extend down into the mediastinum or 
laterally to present as neck abscess173. When involving the thoracic vertebra, 
can extend into mediastinum and present as abscess and when involving the 
lumbar spine, can track along psoas sheath and present as psoas abscess, which 
can extend further down to the scarpa’s triangle and gluteal region173. 
 Tuberculosis of hip and knee joint can present with pathological 
fractures. The clinical manifestations depending on the site involved include 
breathlessness, difficulty in swallowing or hoarseness of voice in cases of 
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retropharyngeal abscess; fixed flexion deformity of hip in cases of psoas 
abscess; pain, reduced range of movement, night cries due to muscle spasm in 
cases of hip & joint tuberculosis173. Paraplegia is the most dreaded 
complication of spinal tuberculosis which most commonly occurs secondary to 
compressive neuropathy173. 
Genitourinary tuberculosis:  
 Genitourinary system is one of the most commonly affected sites by 
haematogenous spread of the bacilli and like all other forms of extra pulmonary 
tuberculosis, it shows an increased incidence in HIV infection174. The 
histomorphological changes vary ranging from parenchymal changes, 
pelvicalyceal system changes, and tuberculous interstitial nephritis to chronic 
renal failure174.  
 Clinical manifestations include flank pain, fever, dysuria and sterile 
pyuria174. Involvement of female genital tract by tuberculosis is one of the 
commonest causes of infertility175. The disease process can involve 
endometrium, fallopian tubes causing extensive adhesions; the symptoms 
include fever, pelvic pain, and altered menstrual pattern175. In male genital 
tract, tuberculosis can affect epididymis, testicular parenchyma, spermatic cord, 
and accessory sex glands with the manifestations including painless or painful 
scrotal mass, sterile pyuria and fever176.    
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Cutaneous tuberculosis:  
 Cutaneous tuberculosis can occur due to exogenous, endogenous or 
autoinoculation of the tubercle bacilli177. The various cutaneous forms of 
tuberculosis include lupus vulgaris, scrofuloderma erythema induratum of 
Bazin, erythema nodosum, lichen scrofulosorum, papulonecrotic tuberculids 
and tuberculosis verrucosa cutis37, 177. It is very difficult to diagnose cutaneous 
tuberculosis clinically, unless biopsy or culture is done177.  
Tuberculosis of Breast:  
 The incidence of tuberculous mastitis is very high in endemic countries 
like India178. Clinically and radiologically, it mimics carcinoma and typically 
affects young, lactating women and the risk factors include multiparity, HIV 
infection and trauma178. The infection can be the result of haematogenous, 
lymphatic or contiguous spread. The manifestations include tender breast mass, 
ulcer, abscess formation with or without discharging sinus, and fever178. 
Ocular Tuberculosis:  
 Ocular tuberculosis occurs in the setting of military tuberculosis. It can 
affect any part of the eye, with choroid being the most common site179.It can 
present as uveitis, choroidal tubercles, or as iridocyclitis179. The clinical 
manifestations include conjunctival congestion, blurred vision and eye pain179. 
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Otorhinolaryngology related Tuberculosis:  
 The commonest site affected by tuberculosis in otorhinolaryngological 
system is larynx, other than cervical lymphadenitis180. IT can however involve 
any site including oral cavity, nasal cavity, nasopharynx, oropharynx, salivary 
glands and middle ear180. Laryngeal tuberculosis typically presents with 
odynophagia, dysphagia and hoarseness of voice and biopsy or culture is 
essential to differentiate it from malignancy180. 
Disseminated/miliary tuberculosis:  
 Miliary tuberculosis, which refers to the disease involvement in two or 
more non-contiguous sites, is a highly lethal form of tuberculosis, where 
widespread lymphatic or haematogenous dissemination of the tuberculous foci 
results in the formation of tiny tubercles on the organs involved, which 
resemble millet seeds in their appearance and hence the name (miliarius in 
Latin means ‘relating to millet seeds’) 181. It accounts for about 20% of all extra 
pulmonary tuberculosis cases and is more common in HIV infected patients181.  
 The factors which predispose to miliary tuberculosis include HIV 
infection, diabetes, smoking, immunosuppressant drugs, transplant recipients, 
chronic renal failure, and pregnancy181. The pathogenesis behind the 
development of miliary tuberculosis is believed to be due to inadequate effector 
T cell response which fails to contain the bacilli, eventually resulting in 
widespread dissemination181. No single symptom or sign is diagnostic of 
miliary tuberculosis; a myriad of manifestations such as peripheral 
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lymphadenopathy, cold abscesses, skin lesions, hepatomegaly, splenomegaly, 
serous cavity effusions and choroid tubercles could be a clue to the 
diagnosis181.  
 Various diagnostic modalities need to be put in place for proper work up 
and even with treatment, it carries a high mortality rate181. Miliary tuberculosis 
has now been classified as pulmonary tuberculosis, because if a person has 
both pulmonary & extra pulmonary tuberculosis, he should be classified as 
having pulmonary tuberculosis36.  
DIAGNOSTIC MODALITIES:  
IMAGING:  
 Conventional radiography (X-ray) and ultrasound remain thepreferred 
initial forms of imaging modalities. Though imaging cannot accurately pinpoint 
the diagnosis, it does give some clues to the nature of the lesions, which 
provides the basis for next line of investigation182. Computerised Tomography 
(CT) and Magnetic Resonance Imaging (MRI) are also used depending on the 
part to be imaged182. Positron emission tomography/computed tomography 
with the use of 18F-fluorodeoxyglucose (18F-FDG PET/CT) is another imaging 
method used principally to distinguish benign from malignant lesions182. 
Increased uptake of 18F-FDG is seen in tuberculous lesions which can be 
helpful in identifying them182.  
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Pulmonary tuberculosis:  
 Imaging in primary pulmonary tuberculosis reveals consolidation, which 
can be either unilobar or multilobar along with enlarged hilar or paratracheal 
lymph nodes with or without calcification182. In post-primary tuberculosis, 
cavity formation is the radiological hallmark, which may progress via 
endobronchial spread classically referred to as the ‘tree-in-bud’ sign182. CT is 
more sensitive than conventional radiography in detecting the parenchymal 
lesions and lymphadenopathy. CT can also differentiate active tuberculosis 
from healed lesions182. 
Lymph node tuberculosis:  
 Imaging cannot reliably differentiate between the causes of 
lymphadenopathy. However, CT & MRI can identify matted lymph nodes, 
necrosis and calcification, which are suggestive of tuberculosis183.  
Pleural & pericardial tuberculosis:  
 Ultrasound & conventional radiography can identify pleural effusion & 
pericardial effusion, while CT & MRI can pick up pleural nodules, thickening, 
pericardial thickening and calcification182. 
Abdominal tuberculosis:  
 CT & MRI can detect circumferential wall thickening and mesenteric 
lymphadenopathy which can mimic carcinomas and inflammatory bowel 
disease and can also detect omental adhesions and mesenteric thickening183. 
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Barium studies are also helpful which can demonstrate ‘pulled up caecum’, 
commonly seen in tuberculosis183. CT & MRI can detect miliary or 
macronodular involvement in hepatosplenic tuberculosis183. 
Neurological tuberculosis:  
 Tuberculous meningitis demonstrates abnormal meningeal enhancement 
on MRI and tuberculomas appear on CT as homogeneous ring-enhancing 
lesions with irregular walls of varying thickness183.  
Bone & joint tuberculosis:  
 MRI is superior to other modalities in imaging of tuberculous 
spondylitis. Involvement of two or more contiguous vertebra with or without 
paravertebral abscess and calcification is diagnostic of Pott’s spine183. CT helps 
in identifying the bony destruction in tubercular arthritis183. 
Genitourinary tuberculosis:  
 Putty kidney (ground glass-like calcification) is the end stage 
tuberculous kidney disease seen on x-ray; Intravenous urography and 
ultrasound can also reliably identify ureteric tuberculosis apart from renal 
tuberculosis183. CT is the most sensitive of all imaging modalities in identifying 
all stages of renal tuberculosis, as well as in detecting the tuberculous lesion of 
male genital tract183. Hysterosalpingography detects the uterine synechiae183. 
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Miliary tuberculosis:  
 Conventional radiography can reliably identify the miliary pattern in 
pulmonary tuberculosis and ultrasound can identify the serous cavity effusions, 
focal lesions in liver, spleen and lymphadenopathy181. 18 FDG PET-CT is a 
potentially useful tool in miliary tuberculosis181.  
SPUTUM MICROSCOPY:  
 For long, sputum microscopy with demonstration of acid fast bacilli had 
been the primary modality for diagnosing pulmonary tuberculosis and is still 
the principal method used in many parts of the world and in India, especially in 
resource constrained settings, because it is rapid and inexpensive184. Early 
morning sputum samples, which are high in bacterial load are collected for 
three consecutive days and examined; swallowed sputum in children aspirated 
by gastric lavage and bronchoalveolar lavage fluid can also be used as samples 
for microscopy184.  
Ziehl-Neelsen staining which is the most commonly employed 
technique among others, utilises the acid fast property of the tubercle bacilli to 
stain them, meaning that the carbol fuchsin dye which is used in the staining 
process stains the bacterial cell wall when heat is applied and after cooling, the 
cell wall resists decolourisation with acid and thus retains the stain while the 
background stain disappears, thus enabling the identification of the rod shaped 
bacili184.  
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As simple as it sounds, this test is not sensitive, with sensitivity ranging 
from 0%-45% and depends on the bacillary load with a minimum of 104 bacilli 
per ml of specimen required for the stain to demonstrate the bacilli.185. 
Fluorescent staining with Auramine-rhodamine is a better alternative given its 
better sensitivity and superiority over conventional acid fast stains like Ziehl-
Neelsen, but requires the use of fluorescent microscopes184. 
TISSUE MICROSCOPY:  
 For easily accessible tuberculous lesions, affecting areas like peripheral 
lymph nodes, breast, and abscesses and even in deep seated tuberculous lesions 
with the help of imaging modalities, Fine Needle Aspiration Cytology is a 
minimally invasive procedure with reasonable accuracy and is helpful in 
identifying the granulomas185. The tissue thus obtained can be used for Ziehl-
Neelsen staining or can be sent for culture, for testing by Nucleic acid 
Amplification Test and for Immunocytocehmistry186.  
Immunocytochemistry is a relatively cheap method with high sensitivity 
& specificity and a wide range of antibodies are available which are directed 
against the mycobacterial antigens like BCG, MPT64, Antigen 5, LAM, 
ESAT6, and HspX186. Histopathological examination of biopsy specimens is 
the preferred method for diagnosing extra pulmonary tuberculosis, though it 
can identify pulmonary tuberculosis also with equal efficacy186. The main 
limitation is the occurrence of granulomas in varied number of causes, which 
can be confusing and in such settings ancillary techniques like Ziehl-Neelsen 
staining and immunohistochemistry can be employed186.  
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IMMUNOHISTOCHEMISTRY:  
 Immunohistochemistry (IHC) has high sensitivity and specificity and 
fares better when compared to acid fast stains, and can identify the antigens 
even in densely necrotic tissues186. IHC refers to the process of detecting 
antigens in the cells using specific antibodies33. The procedure was 
conceptualized and initialized by Dr. Albert Coons in 1941. A number of ways 
are present to visualize the antigen-antibody interaction33. 
 The most common method in routine use is where the antibody is 
conjugated to an enzyme like peroxidase which catalyses a colour producing 
reaction. Other methods include use of antibody tagged to a fluorophore like 
fluorescein or rhodamine33.  
Steps:  
 1. Tissue processing and antigen or epitope retrieval 
  a. 10% neutral buffered formalin is the preferred fixative. 
  b. These fixatives cause certain reversible changes in tertiary and 
   quaternary structure of proteins. 
  c. Formalin fixed paraffin embedded tissue sections are cut 4 to 5 
   microns thick and mounted on to glass slides. 
  d. Trypsin or protease enzyme digestion 
  e. Heating in buffered solutions like citrate or ethylene diamine 
tetra acetic acid (EDTA) buffer in either a microwave oven or pressure cooker 
to retrieve or unmask the antigens that have been altered by  formalin fixation 
 2. Antigen-antibody interaction  
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  - Either the direct or indirect method is used 
 3. Visualizing with detection systems 
  - Antibody molecules can be labelled with either fluorescent 
compounds or active enzymes. Horse radish peroxidase (HRP) enzyme is 
commonly used. The chromogens are oxidized by HRP enzyme, giving a 
resultant brown or red coloured staining33. 
CULTURE:  
 Isolation of mycobacteria by culture is the gold standard for diagnosis of 
tuberculosis, based on which the definitive diagnosis is made185. The main 
drawback is that it is time consuming and can take anywhere between up to 6 
weeks, before a conclusive result is arrived at, which affects the time to 
treatment186. This can be overcome with newer culture systems like Myco/F 
Lytic and the BacT/Alert culture systems, which provide results in as little as 
16 days184.  
 The major advantage of culturing is that apart from the definitive 
diagnosis, drug susceptibility testing can also be done185. Any type of specimen 
viz. sputum, gastric lavage, blood, urine, body fluids, and stools can be used for 
culture, as also tissues and tissue aspirates, provided they are sent in normal 
saline184. All of the specimens need decontaminating procedures with N-acetyl-
L-cysteine and sodium hydroxide, to kill the contaminating bacteria which may 
overgrow the mycobacteria when present and also various antibiotics which 
prevent the growth of the contaminating bacteria184.  
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 Culturing can be done using solid media or liquid media. Traditionally 
Lowenstein-Jensen medium, which is an egg based solid medium, is suitable in 
most conditions184. Various semi-automated broth-based culture systems like 
BACTEC MGIT 960 system, the VersaTREK system, and the MB/BacT are 
available which improve the yield by 10% over solid media and also improves 
the turnaround time184. These new systems can also detect atypical 
mycobacterial colonies as well, and positive cultures are subcultured to solid 
media to detect mixed cultures and for correlation with any colony 
morphologies present184,186. 
SEROLOGICAL TESTS:  
 Though a wide number of serological tests are available which detect 
the antibodies (IgM, IgG, IgA) in the serum against various mycobacterial 
antigens, WHO does not recommend the use of these tests for routine 
diagnostic purposes, as it has very low specificity and very low accuracy, found 
out on a Meta analysis186. These tests had been in routine use previously, 
because it was simple, rapid and cheap, however the government of India has 
banned the manufacture and use of serodiagnostic test kits in an order dated 
07.06.2012 based on the WHO recommendations187. 
IMMUNOLOGICAL TESTS:  
 Tuberculin skin test popularly known as the Mantoux test or Pirquet test 
or Purified Protein Derivative test has been in vogue for more than 100 years, 
used for screening of tuberculosis infection186. It is an example of delayed type 
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hypersensitivity reaction (Type IV), where the previously sensitised T-cells due 
to previous infection are recruited to the skin site where they release 
lymphokines causing a measurable response i.e., induration186.  
 A small amount of purified protein derivative tuberculin is injected into 
the volar aspect of forearm and the result is read at 48 hours. Induration 
develops if the individual has been exposed to the bacilli186. The test does not 
differentiate between active tuberculosis, prior infection, BCG vaccination, or 
sensitization by Non tuberculous mycobacteria186. However, it is still widely 
used as the initial screening test186.  
Interferon gamma (IFN-γ) is a macrophage activating cytokine which 
plays an important role in regulating the cell-mediated immune response to M. 
tuberculosis infection IFN-γ-release assays are in vitro tests which stimulate the 
T-cells in peripheral blood to release IFN-γ in response in response to 
mycobacterial antigens such as ESAT-6 and CFP-10, which are then 
measured186. There are two commercially available Interferon gamma release 
assays namely Quantiferon TB Gold, & T-SPOT.TB186.  
Studies have shown that these assays have better sensitivity (75%) than 
Mantoux test and very high specificity (94%) 186. BCG vaccination does not 
alter the results, however the assays cannot differentiate between active 
tuberculosis and latent infection186. Nevertheless, it is a better alternative to the 
Mantoux test186. 
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Adenosine deaminase is an enzyme involved in the conversion of 
adenosine to inosine, in the purine catabolism, and is known to exist as two 
isoenzymes viz. ADA-1 & ADA-2186. While ADA-1 is produced by most cells, 
ADA-2 is believed to be produced by lymphocytes & monocytes and occurs in 
negligible quantities186. The interaction of mycobacterium with the immune 
system results in the production of ADA by the activated T lymphocytes & 
monocytes and ADA-2 levels have been found to occur in high quantities in 
tuberculosis and thus the measurement of ADA activity has been found to be 
useful in the diagnosis of extra pulmonary tuberculosis especially in the setting 
of tuberculous serous cavity effusions like pleural fluid, pericardial fluid, and 
ascitic fluid186. 
NUCLEIC ACID AMPLIFICATION TESTS:  
 Molecular methods like Nucleic acid amplification tests amplifies the 
DNA/RNA of the pathogen, and is a diverse group of tests that includes 
Polymerase Chain Reaction (PCR), Ligase Chain Reaction (LCR), 
Transcription Mediated Amplification (TMA) and Nuclei Acid Sequence 
Based Amplification (NASBA)186. The tests are highly sensitive and highly 
specific with a positive predictive value approaching 99%, and the results are 
available on the same day & can detect as few as 10 mycobacteria186.  
 PCR technique is commonly used which includes conventional PCR, 
Nested PCR and Real-time PCR186. Besides the diagnosis, drug susceptibility 
testing can also be performed by NAAT186.World Health Organisation has 
approved the use of Xpert MTB/RIF, a cartridge based nested PCR technique, 
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as the initial diagnostic technique for the diagnosis of pulmonary tuberculosis 
as well as extra pulmonary tuberculosis, based on meta-analysis186.  
 Various studies have demonstrated the efficacy of Xpert MTB/RIF in 
diagnosing extra pulmonary tuberculosis, with sensitivity ranging from 50% - 
100% and specificity of more than 80%188. The major drawbacks of these 
methods are their high cost, low sensitivity in smear negative cases and 
extreme sensitivity to contamination which may result in high false positive 
rates186.  
TREATMENT:  
 The Revised National Tuberculosis Control Programme (RNTCP), in its 
2016 guidelines, has recommended the use of multi drug regimen in the 
intensive phase (IP) and consolidation phase (CP) 189. For all new cases of 
tuberculosis, irrespective of pulmonary or extra pulmonary, the use of Isoniazid 
(H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), in daily or intermittent 
doses for a period of 2 months in IP (2HRZE) and the use of  HRE for 4 
months in the CP (4HRE) 189. For all previously treated tuberculosis cases, the 
addition of Streptomycin (S) injection for 1 month in the IP is advised, which is 
as follows: 2HRZES+1HRZE in the IP and 5HRE in the CP189. 
 For multidrug resistant tuberculosis (MDR-TB), the patients are to be 
treated with a standard regimen of Kanamycin, Levofloxacin, Ethambutol, 
Pyrazinamide, Ethionamide and Cycloserine for 6 to 9 months in the IP and 18 
months of CP with Levofloxacin, Ethambutol, Ethionamide and Cycloserine189.  
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 For extremely drug resistant tuberculosis (XDR-TB), 6 to 12 months of 
IP with Capreomycin, Para Amino Salicylic acid, Moxifloxacin, High dose 
Isoniazid, Clofazimine, Linezolid and Co-Amoxyclav, followed by 18 months 
of CP with Para Amino Salicylic acid, Moxifloxacin, High dose Isoniazid, 
Clofazimine, Linezolid and Co-Amoxyclav189. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 This is a prospective and retrospective study conducted at the Institute 
of Pathology, Madras Medical College & Rajiv Gandhi Government General 
Hospital, Chennai for a 2 year study period from August 2015 to July 2017. 
Out of the 24617 cases of histopathological specimens received, 349 cases 
were granulomatous lesions in extra pulmonary sites, out of which 198 cases 
were of suspected tuberculous etiology based on the clinical suspicion, 
presence of necrosis with or without caseation or Langhans giant cells. The 
remaining 151 cases were of different aetiologies viz. fungal infection, foreign 
body induced, inflammatory bowel disease and vasculitis.  
DATA COLLECTION:  
 Case details especially age, sex, presenting complaints, details of 
relevant investigations, procedure done and histopathological diagnosis of the 
tissues were obtained from pathology registers. Relevant details like clinical 
diagnosis, imaging findings, prior history of anti-tuberculous therapy, history 
of Human Immunodeficiency Virus (HIV) infection, immunocompromised 
status were also noted. Haematoxylin and Eosin sections of the paraffin tissue 
blocks were reviewed. Out of the 198 granulomatous lesions of suspected 
tuberculous etiology in extra pulmonary sites, 50 cases were selected by 
proportional representation of the organ systems involved and their 
corresponding tissue blocks were obtained for immunohistochemical analysis 
of Mycobacterium tuberculosis using polyclonal antibody and Ziehl- Neelsen 
staining for the visualisation of the acid fast bacilli. 
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CONTROLS: 
Positive Control:  
 Formalin fixed, paraffin embedded tissue section of Mycobacterium 
tuberculosis infected lung tissue which were positive for AFB by Ziehl-Neelsen 
staining was used as positive control 
Negative Control:  
 Formalin fixed, paraffin embedded tissue sections of foreign body 
granuloma was used as negative control. 
TABLE 1: PROCEDURE OF IMMUNOHISTOCHEMISTRY 
Antigen Vendor 
Species 
(clone) 
Positive Control 
Negative 
Control 
Mycobacterium 
tuberculosis 
Biocare 
Medical 
Rabbit 
polyclonal 
M. Tuberculosis 
Infected Lung 
Tissue 
Foreign body 
granuloma 
 
IMMUNOHISTOCHEMISTRY (IHC): 
1. 4 micron thick sections were cut from formalin fixed paraffin embedded 
tissue blocks and transferred onto positively charged glass slides. 
2. The glass slides were kept in an incubator at 58 degree Celsius 
overnight. 
3. Deparaffinisation in xylene for 15 minutes x 2 changes 
4. Dehydration with absolute alcohol for 5 minutes x 2 changes 
5. Washing of sections in tap water for 10 minutes 
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6. Washing of sections in distilled water for 5 minutes 
7. Retrieval of antigens done with microwave oven with sections immersed 
in Tris-EDTA buffer (preheated at 800 watts for 4 minutes) for 20 
minutes 
 A. 800 watts – 5 minutes 
 B. 640 watts – 10 minutes 
 C. 480 watts – 5 minutes 
8. Cool the slides to room temperature and then wash with distilled water 
for 10 minutes 
9. Then wash in phosphate wash buffer for 5 minutes x 2 changes 
10. Application of peroxide block over the sections for 5 minutes 
11. Slides are washed with phosphate wash buffer for 5 minutes 
12. Primary antibody was applied over the sections and incubated for 45 
minutes 
13. After washing in wash buffer for 5 minutes, HRP-conjugated polymer 
applied to the sections and incubated for 30 minutes 
14. Slides were washed with 2 changes of wash buffer for 2 minutes each 
15. Sections are then covered with Di-amino benzidine (DAB) chromogen 
(prepared by diluting 1 drop of DAB chromogen to 1ml of DAB buffer) 
for 5 minutes. 
16. Counterstaining was done with haematoxylin, washed in running tap 
water, air dried, cleared with xylene and mounted. 
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INTERPRETATION AND SCORING OF IHC: 
 The IHC slides were analysed for the presence of reaction, cellular 
localisation of the staining – mycobacterium tuberculosis shows fine or coarse 
granular cytoplasmic dust-like positive staining within the epithelioid 
histiocytes, giant cells and in extracellular locations like areas of necrosis. 
Percentage of cells taking up the stain and the intensity with which they stain 
were also analysed. Scores of 1, 2 and 3 were assigned to mild, moderate and 
strong intensity staining respectively. 
TABLE 2: PROCEDURE FOR ZIEHL- NEELSEN STAINING 
Vendor Positive Control Negative Control 
Fisher 
Scientific 
M. Tuberculosis Infected Lung 
Tissue 
Foreign body 
granuloma 
 
ZIEHL – NEELSEN STAINING: 
1. Deparaffinise the sections in 2 changes of Xylene for 15 minutes 
each 
2. Immerse the slides in 2 changes of absolute alcohol for 5 minutes 
each. Air dry the slides. 
3. Flood the slide with carbol fuchsin solution, and allow to stand at 
37°C for 1 hour 
4. Rinse in tap water until no colour washes off. 
5. Dip in 1% acid-alcohol until the sections are light pink. 
6. Counter stain with methylene blue for 5 minutes 
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7. Rinse well with tap water. 
8. Dehydrate & clear with xylene and mount with coverslip.  
INTERPRETATION OF ZIEHL-NEELSEN STAINING: 
 When stained with strong stains (carbol fuchsin), acid acid-fast bacilli 
retain their colour even after treatment with strong decolourizing solutions due 
to the presence of the mycolic acids which takes up the stain and remains 
resistant to decolourization with 1% acid-alcohol or 20% sulphuric acid as 
compared to other tissues. They remain red after counterstaining with 
methylene blue, whereas the other tissues and microorganisms which are 
susceptible to acid take on the blue colour. Acid fast bacilli appear bright red 
curved rods and background appears blue.  
STATISTICAL ANALYSIS: 
 Statistical analysis was performed with IBM Statistical Package for the 
Social Sciences software version 20.0. The immunohistochemical expression of 
MTB antibody and Ziehl-Neelsen staining were correlated and studied using 
McNemar test and chi square test. 
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OBSERVATION AND RESULTS 
 In the 24 month study period performed from August 2015 to July 2017, 
a total of 24617 specimens were received at the Institute of Pathology, Madras 
Medical College & Rajiv Gandhi Government General Hospital for 
histopathological examination. Out of the total 24617 specimens, 50 cases 
which were selected by proportional representation were taken up for study 
with immunohistochemical analysis and Ziehl-Neelsen staining. 
 The sites of the selected lesions are listed below (Table 3, Chart 1) 
TABLE 3: FREQUENCY OF GRANULOMATOUS LESIONS IN 
SPECIFIC SITES 
SITE FREQUENCY PERCENT CUMULATIVE % 
Bone Marrow 1 2% 2% 
Breast 1 2% 4% 
Intestine 8 16% 20% 
Liver 1 2% 22% 
Lymph Node 22 44% 66% 
Omentum 1 2% 68% 
Peritoneum 4 8% 76% 
Soft Tissue 7 14% 90% 
Synovium 1 2% 92% 
Urinary  Bladder 1 2% 94% 
Vertebra 3 6% 100% 
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CHART 1: FREQUENCY OF GRANULOMATOUS LESIONS IN 
SPECIFIC SITES 
 
 Lymph nodes accounted for the majority of extra pulmonary 
granulomatous lesions, constituting about 44% of all lesions, followed by 
Intestine (16%), soft tissues (14%), peritoneum (8%) and vertebra (6%). Other 
rare sites of occurrence included bone marrow, breast, liver, omentum, 
synovium and urinary bladder which all accounted for 2% each. 
 
2% 2%
16%
2%
44%
2%
8%
14%
2%
2%
6%
Sites
Bone Marrow Breast
Intestine Liver
Lymph Node Omentum
Peritoneum Soft Tissue
Synovium Urinary Bladder
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Majority of the cases had a peak incidence in the age group 21-40 years 
which constituted about 60% followed by the age group of above 40 years 
which formed about 32%. Mean age is about 34.56 years (Table 4, Chart 2) 
TABLE 4: AGE WISE DISTRIBUTION OF THE LESION 
 
AGE GROUP FREQUENCY PERCENT 
<20 YEARS 4 8% 
21-40 YEARS 30 60% 
ABOVE 40 YEARS 16 32% 
TOTAL 50 100% 
 
CHART 2: AGE WISE DISTRIBUTION OF THE LESION
 
  
8%
60%
32%
AGE GROUP
<20 YEARS
21-40 YEARS
>40 YEARS
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There was not much significant difference in the sex with males accounting for 
52% and females accounting for 48% of cases. (Table 5,  
Chart 3) 
TABLE 5: SEX WISE DISTRIBUTION 
SEX FREQUENCY PERCENT 
MALE 26 52% 
FEMALE 24 48% 
Total 50 100% 
 
CHART 3: SEX WISE DISTRIBUTION 
 
MALE
52%
FEMALE
48%
SEX
MALE FEMALE
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 Among the 50 cases, only one patient was positive for Human 
Immunodeficiency Virus (HIV), who presented with cervical 
lymphadenopathy. (Table 6, Chart 4) 
TABLE 6: HIV STATUS 
HIV STATUS FREQUENCY PERCENT 
Negative 49 98% 
Positive 1 2% 
Total 50 100% 
 
CHART 4: HIV STATUS 
 
 
 
98%
50 year old male 
with cervical 
lymph node 
swelling.
On Anti retro viral 
therapy 
2%
HIV Status
Negative Positive
48 
 
Among the 50 cases, 5 of the patients has previously undergone anti-
tuberculous therapy. (Table 7, Chart 5) 
TABLE 7: ANTI-TUBERCULOUS THERAPY HISTORY 
ANTI-TUBERCULOUS 
THERAPY HISTORY 
FREQUENCY PERCENT 
Treated 5 10% 
Untreated 45 90% 
Total 50 100% 
 
CHART 5: ANTI-TUBERCULOUS THERAPY HISTORY 
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Among the 50 granulomatous lesions, on histopathological examination 
(H&E), necrosis was present in 24 cases which constituted about 48% of cases. 
(Table 8, Chart 6) 
TABLE 8: PRESENCE OF NECROSIS ON HISTOPATHOLOGICAL 
EXAMINATION 
NECROSIS FREQUENCY PERCENT 
ABSENT 26 52.0 
PRESENT 24 48.0 
Total 50 100.0 
 
CHART 6: PRESENCE OF NECROSIS ON HISTOPATHOLOGICAL 
EXAMINATION 
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 All 50 cases were subjected to immunohistochemical analysis using 
polyclonal anti mycobacterium tuberculosis antibody. 41 cases showed 
cytoplasmic (antigenic dust) positivity (Table 9, Chart 7) 
TABLE 9: IMMUNOHISTOCHEMICAL ANALYSIS 
IMMUNOHISTOCHEMISTRY FREQUENCY PERCENT 
POSITIVE 41 82% 
NEGATIVE 9 18% 
Total 50 100% 
 
CHART 7: IMMUNOHISTOCHEMICAL ANALYSIS 
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All 50 cases were subjected to Ziehl-Neelsen staining as well. 6 cases 
turned positive for the tubercle bacilli. (Table 10, Chart 8) 
TABLE 10: ZIEHL-NEELSEN STAIN 
ZIEHL-NEELSEN STAIN FREQUENCY PERCENT 
POSITIVE 6 12% 
NEGATIVE 44 88% 
Total 50 100% 
 
CHART 8: ZIEHL-NEELSEN STAIN 
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14 out of 17 cases which had a clinical suspicion of tuberculosis were 
positive by immunohistochemical staining, whereas 27 out of the remaining 33 
cases were positive by immunohistochemical staining. (Table 11, Chart 9) 
TABLE 11: COMPARISON OF CLINICAL SUSPICION OF 
TUBERCULOSIS WITH IMMUNOHISTOCHEMISTRY 
Clinical suspicion of tuberculosis * Immunohistochemistry Cross 
tabulation 
 
Immunohistochemistry 
Total 
Positive Negative 
 
Clinical 
Suspicion of 
Tuberculosis 
No 
Count 27 6 33 
% within 
IHC 
65.9% 66.7% 66.0% 
Yes 
Count 14 3 17 
% within 
IHC 
34.1% 33.3% 34.0% 
 
 
Total 
Count 41 9 50 
% within 
IHC 
100.0% 100.0% 100.0% 
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CHART 9: COMPARISON OF CLINICAL SUSPICION OF 
TUBERCULOSIS WITH IMMUNOHISTOCHEMISTRY 
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2 out of 17 cases which had a clinical suspicion of tuberculosis were positive 
by Ziehl-Neelsen staining, whereas 4 out of the remaining 33 cases were 
positive by Ziehl-Neelsen staining. (Table 12, Chart 10) 
TABLE 12: COMPARISON OF CLINICAL SUSPICION OF 
TUBERCULOSIS WITH ZIEHL-NEELSEN STAINING 
CLINICAL SUSPICION OF TUBERCULOSIS * ZIEHL-NEELSEN 
STAINING CROSSTABULATION 
 
Ziehl-Neelsen staining 
Total 
Positive Negative 
 
Clinical 
Suspicion of 
Tuberculosi
s 
No 
Count 4 29 33 
% within Ziehl-
Neelsen Staining 
66.7% 65.9% 66.0% 
Yes 
Count 2 15 17 
% within Ziehl-
Neelsen staining 
33.3% 34.1% 34.0% 
 
 
Total 
Count 6 44 50 
% within Ziehl-
Neelsen Staining 
100.0% 100.0% 100.0% 
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CHART 10: COMPARISON OF CLINICAL SUSPICION OF 
TUBERCULOSIS WITH ZIEHL-NEELSEN STAINING 
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Out of the 9 cases which were negative for immunohistochemistry, the tissue 
samples were lymph node (2), intestine (2), soft tissue (1), vertebra (1), liver 
(1), peritoneum (1) and urinary bladder (1). (Table 13, Chart 11)  
TABLE 13: COMPARISON OF ORGAN SYSTEMS WITH 
IMMUNOHISTOCHEMICAL EXPRESSION 
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CHART 11: COMPARISON OF ORGAN SYSTEMS WITH 
IMMUNOHISTOCHEMICAL EXPRESSION 
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Presence of necrosis had no effect on the expression of immunohistochemistry, 
with P value more than 0.005 (Table 14, Chart 12) 
TABLE 14: CORRELATION OF NECROSIS WITH 
IMMUNOHISTOCHEMICAL EXPRESSION 
NECROSIS - IMMUNOHISTOCHEMISTRY CROSS TABULATION 
 
IMMUNOHISTOCHEM
ISTRY 
Total 
POSITIVE NEGATIVE 
NECROSIS 
PRESENT 
Count 23 1 24 
% within Immuno 
histochemistry 
56.1% 11.1% 48.0% 
ABSENT 
Count 18 8 26 
% within Immuno 
histochemistry 
43.9% 88.9% 52.0% 
TOTAL 
Count 41 9 50 
% within Immuno 
histochemistry 
100.0% 100.0% 100.0% 
 
Pearson Chi-Square=5.984* p=0.014 
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CHART 12: CORRELATION OF NECROSIS WITH 
IMMUNOHISTOCHEMICAL EXPRESSION 
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Prior treatment with anti-tuberculous drugs had no effect on the 
immunohistochemical expression with P value more than 0.005 (Table 15, 
Chart 13) 
TABLE 15: CORRELATION OF ANTI-TUBERCULOUS THERAPY 
WITH IMMUNOHISTOCHEMICAL EXPRESSION 
Anti-tuberculous Therapy * Immunohistochemistry Crosstabulation 
 
 
Immunohistochemistry 
Total 
Positive Negative 
 
Anti-
tuberculous 
therapy 
Treated 
Count 5 0 5 
% within 
IHC 
12.2% 0.0% 10.0% 
Untreate
d 
Count 36 9 45 
% within 
IHC 
87.8% 100.0% 90.0% 
 
 
Total 
Count 41 9 50 
% within 
IHC 
100.0% 100.0% 100.0% 
 
Pearson Chi-Square=1.220  p=0.269 
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CHART 13: CORRELATION OF ANTI-TUBERCULOUS THERAPY 
WITH IMMUNOHISTOCHEMICAL EXPRESSION 
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Out of the 41 cases which were positive by immunohistochemistry, 22 cases 
had strong intensity staining (score 3) and 19 cases had moderate staining 
intensity (score 2). 3 cases had mild intensity staining (score 1) and were 
considered as negative along with the remaining 6 cases. The presence of 
necrosis had no impact on the staining intensity. (Table 16, Chart 14) 
TABLE 16: COMPARISON OF NECROSIS WITH INTENSITY OF 
IMMUNOHISTOCHEMICAL EXPRESSION 
Necrosis * Immunohistochemistry Staining Intensity Crosstabulation 
 
 
Immunohistochemistry 
Total 
Negative/
Score 1 
Score 2 Score 3 
 
Necrosis 
Present 
Count 3 12 9 24 
% within 
IHC 
33.3% 63.2% 40.9% 48% 
Absent 
Count 6 7 13 26 
% within 
IHC 
66.7% 36.8% 59.1% 52% 
 
 
Total 
Count 9 19 22 50 
% within 
IHC 
100.0% 100.0% 100.0% 100.0% 
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CHART 14: COMPARISON OF NECROSIS WITH INTENSITY OF 
IMMUNOHISTOCHEMICAL EXPRESSION 
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12% of cases were positive for acid fast bacilli by Ziehl-Neelsen staining, 
whereas 82% of cases were positive by immunohistochemical staining. The P 
value is less than 0.001 by McNemar test which is statistically significant 
which shows the sensitivity of immunohistochemistry is better than Ziehl-
Neelsen staining. (Table 17, Chart 15) 
TABLE 17: COMPARISON OF IMMUNOHISTOCHEMICAL 
STAINING WITH ZIEHL-NEELSEN STAINING 
Immunohistochemistry * Ziehl-Neelsen Stain Cross tabulation 
 
Ziehl-Neelsen Stain 
Total 
POSITIV
E 
NEGATIV
E 
Immuno 
histochemistr
y (IHC) 
POSITIVE 
Count 6 35 41 
% within 
IHC 
14.6% 85.4% 
100.0
% 
NEGATIVE 
Count 0 9 9 
% within 
IHC 
0.0% 100.0% 
100.0
% 
Total 
Count 6 44 50 
% within 
IHC 
12.0% 88.0% 
100.0
% 
 
McNemar Test P<0.001 
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CHART 15: COMPARISON OF IMMUNOHISTOCHEMICAL 
STAINING WITH ZIEHL-NEELSEN STAINING 
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COLOUR PLATES 
  
 Bone marrow showing epithelioid granuloma (H&E, 100x)  
 
 
Epithelioid granuloma with Langhans giant cell (H&E, 400x)  
(Lesion in Urinary bladder) 
  
Breast parenchyma showing epithelioid granuloma (H&E, 100x) 
 
 
Epithelioid granuloma with Langhans giant cells in breast  
(H&E, 400x) 
  
Liver parenchyma with epithelioid granuloma (H&E, 100x)  
 
 
Liver parenchyma with epithelioid granuloma and Langhans  
giant cells (H&E, 400x)  
 
 Lymph node parenchyma with multiple epithelioid granuloma  
and areas of necrosis (H&E, 40x)  
 
 
Lymph node parenchyma with epithelioid granuloma, areas of necrosis and 
Langhans giant cells (H&E, 100x)  
  
Omentum showing epithelioid granuloma with Langhans  
giant cell (H&E, 100x)  
 
 
Peritoneum showing epithelioid granuloma with Langhans  
and foreign body type of giant cells (H&E, 100x)  
  
Epithelioid granuloma and Langhans giant cell (H&E, 400x)  
(Lesion in soft tissue) 
 
 
Bony spicules with epithelioid granuloma and Langhans giant  
cells (H&E, 100x) (Lesion in vertebra)  
  
IHC : Positive staining within the granulomas and  
multi nucleated giant cells (100x)  
 
IHC : Positive staining within the granulomas and  
multi nucleated giant cells (100x)  
 IHC : Absent / Negative staining in the granuloma (400x)  
 
 
IHC : Mild intensity staining – Score 1 (400x)  
 
 IHC : Moderate intensity – Score 2 – Cytoplasmic granular  
staining within the epithelioid histiocytes and multinucleated  
giant cells (400x)  
 
IHC : Strong intensity staining – Score 3 – Cytoplasmic granular  
staining within the epithelioid histiocytes and multinucleated  
giant cells (400x)  
 Ziehl – Neelsen stain showing acid fast tubercle bacilli  
(Bright Red) in a blue background 
 
 
Ziehl – Neelsen stain showing acid fast tubercle bacilli  
(Bright Red) in a blue background (Oil immersion) 
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DISCUSSION 
Tuberculosis is the leading cause of death among infectious diseases in 
India, which incidentally has the highest tuberculosis burden in the world. 
Early diagnosis and treatment of tuberculosis, with the disease being curable 
makes it all the more pertinent. The diagnosis of extra pulmonary tuberculosis 
has always been a stumbling block.  
Lymph node tuberculosis accounts for the majority of extra pulmonary 
tuberculosis. In the study by Khandkar et al, lymph node involvement was seen 
in 51% cases of extra pulmonary tuberculosis190.  
In the study by Sharma et al, lymph node involvement accounted for 
35% of extra pulmonary tuberculosis191. 
In the study by Dandapat et al, 41.5% cases of extra pulmonary 
tuberculosis were lymph node tuberculosis191. 
In the study by Jha et al, lymph node tuberculosis accounted for 63% of 
extra pulmonary tuberculosis191. 
In the study by Castro et al, 46% of extra pulmonary tuberculosis cases 
were lymph node tuberculosis191. 
In the present study, 44% cases of extra pulmonary tuberculosis were 
lymph node tuberculosis. 
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TABLE 18: INCIDENCE OF LYMPH NODE TUBERCULOSIS 
AMONG EXTRAPULMONARY TUBERCULOSIS 
STUDY 
PERCENTAGE OF LYMPH NODE 
TUBERCULOSIS AMONG  EPTB 
Khandkar et al 51% 
Sharma et al 35% 
Dandapat et al 41.5% 
Jha et al 63% 
Castro et al 46% 
Present Study 44% 
 
There is not much of a difference in the sex distribution in extra 
pulmonary tuberculosis, with many studies showing a slight male 
preponderance. 
In the study by Shrivatsava et al, the male: female ratio was 1.16:1 
(Males: 53.8%, Females: 46.2%) 192. 
In the study by Prakasha et al, the male: female ratio was 1.06:1 (Males: 
51.5%, Females: 48.5%) 193. 
In the study by Bag et al, the male:female ratio was 1.4:1 (Males: 
58.4%, Females: 41.6%) 194. 
In the present study, the male: female ratio is 1.08:1 (Males-52%, 
Females-48%) 
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TABLE 19: SEX DISTRIBTUION OF PATIENTS WITH EXTRA 
PULMONARY TUBERCULOSIS 
STUDY MALES FEMALES 
MALE: FEMALE 
RATIO 
STUDY 
SAMPLE 
Shrivatsava et al 53.8% 46.2% 1.16: 1 130 
Prakasha et al 51.5% 48.5% 1.06: 1 528 
Bag et al 58.4% 41.6% 1.4: 1 2596 
Present study 52% 48% 1.08: 1 50 
 
In the study by Shrivatsava et al, the age group of 21-40 years had the 
highest proportion of extra pulmonary tuberculosis accounting for 41.53% 192.  
In the study by Jamil et al, 49.17% of cases were in the third and fourth 
decade group 195. 
In the study by Gaur et al, 59.2% of cases of extra pulmonary 
tuberculosis were in the third and fourth decade196. 
In the present study, the major proportion (60%) of cases of extra 
pulmonary tuberculosis (presumptive diagnosis) were in the third and fourth 
decade of life. 
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TABLE 20: COMMON AGE DISTRIBUTION OF PATIENTS WITH 
EXTRA PULMONARY TUBERCULOSIS 
STUDY 
PERCENTAGE OF PATIENTS IN 
THIRD & FOURTH DECADE OF LIFE 
STUDY 
SAMPLE 
Shrivatsava et al 41.53% 130 
Jamil et al 49.17% 769 
Gaur et al 59.2% 252 
Present study 60% 50 
 
Presence of the mycobacterial antigens can be elicited by 
Immunohistochemistry as shown by several studies which are mentioned later 
and our present study. Positive cases show coarse or fine granular cytoplasmic 
staining corresponding to the fragments of TB bacilli or intact bacilli can be 
seen within the macrophages, fibroblasts, plasma cells, lymphocytes and even 
endothelial cells outside the granuloma197.  
One of the major limitations of immunohistochemistry technique is the 
background staining which may cause increased false positive rate, especially 
if the interpreter is unfamiliar with the technique. Proper antibody dilution, 
reducing endogenous enzyme interference with peroxide blocking reagents are 
necessary to reduce the background staining. 
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Another major limitation of polyclonal mycobacterium tuberculosis 
antibody is the cross reactivity with non-tuberculous mycobacteria like M. 
avium, M. phlei, and M. parafortuitum, which can be overcome by using 
species specific monoclonal antibody. 
In the study by Humphrey et al, IHC positivity was 77.7% among a 
sample of 59 cases198. 
In the study by Barbolini et al, all 23 cases in the study were positive by 
IHC staining198. 
In the study by Padmavathy et al, immunohistochemistry was positive in 
34 out of 50 cases198. 
In the study by Goel at al, the positivity rate for immunohistochemistry 
was 100%198. 
In the study by Purohit et al, two types of antibodies (anti-MPT and anti-
BCG) were used for 120 cases, the positivity rate of each was 80% and 76.6% 
respectively197. 
In the study by Baba et al, two types of antibodies viz. anti-MPT and 
anti-BCG were used. The positivity of each antibody was 80% and 48% 
respectively198. 
In the present study, immunohistochemical analysis revealed positivity 
in 41 out of 50 cases, which translated to a positivity rate of 82% 
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TABLE 21: IMMUNOHISTOCHEMISTRY POSITIVITY IN EXTRA 
PULMONARY TUBERCULOSIS 
STUDY 
METHOD & ANTIBODY 
USED 
SAMPLE 
SIZE 
IHC 
POSITIVITY 
Humphrey et al 
Immunoperoxidase-anti 
peroxidase; polyclonal anti 
-BCG 
59 77.7% 
Barbolini et al 
Indirect avidin-biotin 
complex; monoclonal 
antibody 
23 100% 
Padmavathy et al 
Indirect 
immunoperoxidase; 
polyclonal anti-BCG 
50 68% 
Goel at al 
Streptavidin-biotin; 
monoclonal antibody 
36 100% 
Purohit et al 
Anti-MPT antibody 
Anti-BCG antibody 
120 
120 
80% 
76.6% 
Baba et al 
Anti-MPT antibody 
Anti-BCG antibody 
25 
25 
80% 
48% 
Present study 
Immunoperoxidase-anti 
peroxidase; polyclonal anti 
-MTB 
50 82% 
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Ziehl-Neelsen staining which is a fast and cheap procedure, has a 
variable sensitivity which depends on the number of bacilli in the tissue. The 
search for the organism is in itself a laborious process, because they are small 
and few in number, besides the fact that the fragmented bacilli are not stained. 
Mycolic acid which is essential for the demonstration of Ziehl-Neelsen 
staining, is soluble in organic solvents which led to the hypothesis that the use 
of various solvents in the tissue processing during formalin fixation and 
paraffin embedding affects the integrity of mycolate which results in the 
frequent negative staining30. 
In a study by Luo D, Ziehl-Neelsen staining was positive in 47 out of 
137 cases (34.3%) 199. 
In a study by Nassaji et al, Ziehl-Neelsen staining was positive in 59 
cases out of 226 cases (26.1%) 200.  
In a study on 252 patients with extra pulmonary tuberculosis by Cagatay 
et al, staining was positive in 17.8% of patients200.  
In another study by Chakravorty et al, the overall positivity of 
conventional smear microscopy was only 3.9% (three of 76) for detecting extra 
pulmonary tuberculosis200. 
Salian et al have shown 25% (15/60) positivity by Ziehl-Neelsen 
staining on histopathological specimens200.  
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In a study conducted by Ajantha et al on 182 tissue samples from 
suspected extra pulmonary tuberculosis cases for testing of Mycobacterium 
tuberculosis, Ziehl-Neelsen staining was positive only in 3.3% of samples200. 
In a study by Padmavathy et al, all the 50 tissue sections were negative 
for AFB by Ziehl-Neelsen staining201. 
In the study by Mukherjee et al., Ziehl-Neelsen staining demonstrated 
the tubercle bacilli in 22 out of 50 cases of lymph node tuberculosis, which 
translates to a positivity rate of 44% 202. 
In the present study, Ziehl-Neelsen staining was positive in 6 out of 50 
cases (12%). 
TABLE 22: ZIEHL-NEELSEN POSITIVITY IN EXTRA PULMONARY 
TUBERCULOSIS 
STUDY SAMPLE SIZE POSITIVITY RATE 
Luo D 137 34.3% 
Nassaji et al 226 26.1% 
Cagatay et al 252 17.8% 
Chakravorty et al 76 3.9% 
Salian et al 60 25% 
Ajantha et al 182 3.3% 
Padmavathy et al 50 0% 
Mukherjee et al 50 44% 
Present Study 50 12% 
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 Literature has shown that studies have been done to compare the results 
of Ziehl-Neelsen staining and immunohistochemistry. 
 In the study by Radhakrishnan et al, in a sample size of 10, the IHC 
positivity was 100% and Ziehl-Neelsen staining positivity was 0%198. 
In the study by Mukherjee et al, IHC positivity was 87% and Ziehl-
Neelsen staining positivity was 44% in a sample of 50 cases198. 
In the study by Padmavathy et al, IHC positivity was 68% and Ziehl-
Neelsen staining was 0% among 50 cases198. 
In the study by Mustafa et al, with a sample of 55 cases, IHC positivity 
was 64% and Ziehl-Neelsen staining positivity was 0%198. 
In the present study the IHC positivity was 82% and Ziehl-Neelsen 
positivity was 12% among 50 cases of extra pulmonary tuberculosis. 
Thus, from the present study and various other studies, it has been 
shown that immunohistochemistry is a better test than Ziehl-Neelsen staining, 
with the positivity rate of immunohistochemistry ranging from 64% to 100% 
(82% in the present study) and the positivity rate of Ziehl-Neelsen staining 
ranging from 0% to 44% (12% in the present study) 
As evidenced by our study, the presence of necrosis and prior treatment 
with anti-tuberculous drugs had no negative impact on the 
immunohistochemical staining characteristics. 
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TABLE 23: COMPARISON OF IHC ANALYSIS AND ZIEHL-
NEELSEN STAINING 
STUDY 
METHOD & 
ANTIBODY USED 
SAMPL
E SIZE 
IHC 
POSITIVITY 
ZIEHL-
NEELSEN 
STAINING 
POSITIVITY 
Radhakrishna
n et al 
Peroxidase-anti-
peroxidase; IgG 
anti mycobacterial 
antibody 
10 100% 0% 
Mukherjee et 
al 
Avidin-biotin 
complex; 
polyclonal anti-
BCG 
50 87% 44% 
Mustafa et al 
Polyclonal anti-
BCG antibody 
55 64% 0% 
Padmavathy 
et al 
Indirect 
Immunoperoxidas
e; 
Polyclonal anti-
BCG 
50 68% 0% 
Kohli et al 
Streptavidin-
biotin; polyclonal 
anti mycobacterial 
antibody 
100 72% 23% 
Present Study 
Immunoperoxidas
e-anti peroxidase; 
polyclonal anti -
MTB 
50 82% 12% 
 
  
 
 
SUMMARY 
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SUMMARY 
 For the study period of two years from August 2015 to July 2017, a total 
of 24617 specimens were received at the Institute of Pathology, Madras 
Medical College & Rajiv Gandhi Government General Hospital for 
histopathological examination. 
 Out of the 24617 cases of histopathological specimens received, 349 
cases were granulomatous lesions in extra pulmonary sites. 
 Out of the 349 cases, 198 cases were of suspected tuberculous etiology 
based on the clinical suspicion, presence of necrosis with or without 
caseation or Langhans giant cells. 
 Lymph nodes accounted for the majority of extra pulmonary 
granulomatous lesions, constituting about 44% of all lesions, followed 
by Intestine (16%), soft tissues (14%), peritoneum (8%) and vertebra 
(6%).  
 Other rare sites of occurrence included bone marrow, breast, liver, 
omentum, synovium and urinary bladder which all accounted for 2% 
each. 
 Maximum incidence of the disease was found in the age group of 21-40 
years which constituted about 60% followed by the age group of above 
40 years which formed about 32%. 
 Males accounted for 52% of the cases with females accounting for 48% 
of cases. 
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 Out of the 50 cases, only one patient had history of infection with 
Human Immunodeficiency Virus (HIV), who presented with cervical 
lymphadenopathy 
 Among the 50 cases, 5 patients had previously undergone anti-
tuberculous therapy. 
 Among the 50 granulomatous lesions, necrosis was present in 24 cases 
on histopathological examination which constituted about 48% of cases 
as opposed to 52% of cases without necrosis. 
 Among the 50 cases which were subjected to immunohistochemical 
analysis using polyclonal anti-mycobacterium tuberculosis antibody, 41 
cases (82%) were positive for tubercle bacilli. 
 Out of the 50 cases which were subjected to Ziehl-Neelsen staining, 6 
cases were positive for the bacilli. 
 14 out of 17 cases in whom there was a clinical suspicion of 
tuberculosis, were positive by immunohistochemical staining, whereas 
27 out of the remaining 33 cases were positive by immunohistochemical 
staining. 
 2 out of 17 cases which had a clinical suspicion of tuberculosis were 
positive by Ziehl-Neelsen staining, whereas 4 out of the remaining 33 
cases were positive by Ziehl-Neelsen staining 
 Presence of necrosis had no effect on the expression of 
immunohistochemistry, with P value more than 0.005 
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 Prior treatment with anti-tuberculous drugs had no effect on the 
immunohistochemical expression with P value more than 0.005 
 Among the 41 cases which were positive by immunohistochemistry, 22 
cases had strong intensity staining (score 3) and 19 cases had moderate 
staining intensity (score 2). 3 cases which had mild / weak intensity 
staining (score 1) along with the remaining 6 cases which had no 
staining were considered as negative. 
 The presence of necrosis had no impact on the staining intensity of 
immunohistochemistry. 
 12% of cases were positive for acid fast bacilli by Ziehl-Neelsen 
staining, whereas 82% of cases were positive by immunohistochemical 
staining. The P value was found to be less than 0.001 by McNemar test 
which is statistically significant which shows that 
immunohistochemistry is better than Ziehl-Neelsen staining for 
localization of the tubercle bacilli. 
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CONCLUSION 
 To conclude, extra pulmonary tuberculosis the commonest presentation 
of which is lymph node tuberculosis poses a diagnostic challenge, which 
necessitates the need for a rapid, cost effective yet sensitive test. The presence 
of necrosis combined with the prior treatment by anti-tuberculous drugs 
compound the diagnostic difficulties.  
 With Ziehl-Neelsen staining, the sensitivity varies across a large 
spectrum from 0% to 45%, making the test less reliable. The sensitivity of the 
test largely depends on the load of bacilli with at least 10,000 bacilli per ml of 
specimen required for the stain to demonstrate the bacilli, which is difficult in 
extra pulmonary tuberculosis due to the less bacillary load. Furthermore, Ziehl-
Neelsen stain can only highlight the intact bacilli, not the fragmented bacilli. 
 With Immunohistochemistry, as evidenced by studies mentioned earlier, 
the sensitivity has fared way better than Ziehl-Neelsen staining. In our study 
too, Immunohistochemistry has been shown to be a better test than Ziehl-
Neelsen staining and can highlight the intact as well as the fragmented bacilli 
within the necrotic areas and remain unaffected by treatment.  
 Immunohistochemistry can be a reasonable if not better alternative to 
Ziehl-Neelsen staining or as an adjunct in the diagnosis of extra pulmonary 
tuberculosis. It is a simple, robust, cheap and sensitive test that can be 
employed in routine pathology laboratories where results can be available in a 
day, prompting early diagnosis and treatment, as opposed to the culture which 
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takes weeks to obtain a result or Polymerase Chain Reaction which is quite 
costly and not available in many of the places in developing countries. Besides 
aiding in the diagnosis, immunohistochemistry also helps in avoiding the 
misdiagnosis, preventing the unwarranted empirical use of anti-tuberculous 
drugs. 
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RECOMMENDATIONS 
1. Further studies with large sample size and employing 
immunohistochemistry, with Polymerase chain reaction/culture as 
the gold standard may be necessary to validate the sensitivity of 
Immunohistochemistry. 
 
2. The use of species specific monoclonal antibody as opposed to the 
polyclonal antibody helps in distinguishing positivity due to cross 
reaction with non-tuberculous mycobacteria. 
 
3. Immunohistochemistry can be a useful and cheap alternative in the 
rapid diagnosis of extra pulmonary tuberculosis. 
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ANNEXURES 
  
ANNEXURE 1 
Class Type Description 
0 
No TB exposure 
Not infected 
No history of exposure 
Negative reaction to tuberculin skin test 
1 
TB exposure 
No evidence of 
infection 
History of exposure 
Negative reaction to tuberculin skin test 
2 
TB infection 
No disease 
Positive reaction to tuberculin skin test 
Negative bacteriologic studies (if done) 
No clinical, bacteriologic, or radiographic 
evidence of TB 
3 
TB, clinically 
active 
M. tuberculosis cultured (if done) 
Clinical, bacteriologic, or radiographic evidence 
of current disease 
4 
TB 
Not clinically 
active 
History of episode(s) of TB 
(or) 
Abnormal but stable radiographic findings 
Positive reaction to the tuberculin skin test 
Negative bacteriologic studies (if done) 
(and) 
No clinical or radiographic evidence of current 
disease 
5 TB suspect 
Diagnosis pending 
TB disease should be ruled in or out within 3 
months 
 
 
 ANNEXURE 2 
 
SCORING SYSTEM FOR IMMUNOHISTOCHEMICAL MARKER 
POLYCLONAL ANTI-MYCOBACTERIUM TUBERCULOSIS 
ANTIBODY (CYTOPLASMIC STAINING) 
INTENSITY OF STAINING SCORE 
ABSENT 0 
MILD 1 
MODERATE 2 
STRONG 3 
 
 
 
 
 
 
 
 
 
 
ANNEXURE 3 - INFORMATION SHEET 
 We are conducting a study on suspected tuberculous lesions among 
patients attending Government General Hospital, Chennai and for that 
your specimen may be valuable to us. 
 The purpose of this study is to aid in the early and rapid diagnosis of 
extra pulmonary tuberculosis with the help of certain special tests and 
immunohistochemical markers. 
 We are selecting certain cases and if your specimen is found eligible, we 
may be using your specimen to perform extra tests and special studies 
which in any way do not affect your final report or management. 
 The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from 
the research, no personally identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will 
not result in any loss of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which 
may aid in the management or treatment. 
 
 
Signature of investigator     Signature of participant 
Date: 
ANNEXURE 4 -B 
Muha;r;rp jfty; jhs; 
Muha;r;rp jiyg;G: re;Njfj;jpw;Fhpa fhr Neha; jpRf;fspy; [Py; ePy;rd; 
epwkpiaAk; ,k;KNdh `;p];Nlhnfkp];l;upiaAk; Xg;gpl;Lghh;f;Fk; Ma;T. 
 
Ma;thsh;  : kU.F.tPuuhftd; 
    Neha;Fwpapay;Jiw 
    nrd;id kUj;Jtf;fy;Y}hp> 
    nrd;id-600 003. 
jq;fsJ jpR (mWit rpfpr;ir nra;ag;gl;lfl;b) ,q;F 
ngw;Wf;nfhs;sg;gl;lJ.  
 ,uh[pt;fhe;jp muR nghJ kUj;Jtkidf;F tUk; Nehahspfsplk; 
,Ue;J ngwg;gl;l re;Njfj;jpw;Fhpa fhr Neha; jpRf;fis gw;wpa xU 
Muha;r;rp ,q;F eilngw;W tUfpwJ. 
 ,e;j jpRf;fspy; Mycobaterium tuberculosis vd;Dk; ghf;lPupah cs;sjh 
vd;gij Muha;tNj ,e;j Ma;tpd; Nehf;fkhFk;. 
 ePq;fSk; ,e;j Muha;r;rpapy; gq;Nfw;f ehq;fs; tpUk;GfpNwhk;. ,e;j 
Muha;r;rpapy; cq;fSila jpRf;fis itj;J rpy rpwg;Gg; ghpNrhjidf;F 
cl;gLj;jp jfty;fis Muha;Nthk;. ,jdhy; jq;fsJ Neha;apd; 
Ma;thpf;ifAk; my;yJ rpfpr;irNah ghjpg;Gf;Fs;shfhJ vd;gijAk; 
njhptpj;Jf; nfhs;fpNwd;. 
KbTfis my;yJ fUj;Jf;fis ntspapLk; NghJk; my;yJ 
Muha;r;rpapd; NghJk; jq;fsJ ngaNuh my;yJ milahsq;fisNah 
ntspapl khl;Nlhk; vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;. 
 ,e;j Muha;r;rpapy; gq;Nfw;gJ jq;fSila tpUg;gj;jpy; Nghpy; jhd; 
,Uf;fpwJ. NkYk; ePq;fs; ve;NeuKk; ,e;j Muha;r;rpapy; ,Ue;J gpd;thq;fyhk; 
vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;.  
 ,e;j rpwg;Gg; ghpNrhjidapd; KbTfis Muha;r;rpapd; NghJ my;yJ 
Muha;r;rpapd; Kbtpd; NghJk; jq;fSf;F mwptpg;Nghk; vd;gijAk; 
njhptpj;Jf; nfhs;fpNwhk;. 
,e;j Ma;itg;gw;wpa re;Njfq;fSf;F njhlh;G nfhs;s Ntz;bath; : 
kU.F.tPuuhftd;> nry; : 7299114346 
gq;Nfw;ghsh; ifnahg;gk;............................. ,lk; : ........................ Njjp: ....................... 
gq;Nfw;ghsh; ngah; kw;Wk; tpyhrk; : 
Muha;r;rpahsh; ifnahg;gk; ........................ ,lk; : ......................... Njjp:...................... 
 
ANNEXURE 5 - INFORMED CONSENT FORM 
 
Title of the study: A COMPARATIVE STUDY ON ZIEHL NEELSEN STAINING 
AND IMMUNOHISTOCHEMICAL ANALYSIS IN SUSPECTED TUBERCULOUS 
LESIONS 
Name of the Participant   : 
Name of the Principal (Co-Investigator) : Dr. G. Veera Raghavan 
Name of the Institution   :Madras Medical College 
Name and address of the sponsor / agency (ies) (if any) : 
 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it has been read 
tome). Iwas free to ask any questions and they have been answered. I am over 18 years of age 
and,exercising myfree power of choice, hereby give my consent to be included as a participant in 
“A COMPARATIVE STUDY ON ZIEHL NEELSEN STAINING AND 
IMMUNOHISTOCHEMICAL ANALYSIS IN SUSPECTED TUBERCULOUS LESIONS”. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study in which the resected soft tissue tumors 
will be subjected to immunohistochemistry and histopathological examination. 
4. I have been explained about my rights and responsibilities by the investigator. I have the right 
to withdraw from the study at any time. 
5. I have been informed the investigator of all the treatments I am taking or have taken in the 
past ________ months including any native (alternative) treatment. 
6. I hereby give permission to the investigators to release the information obtained from me as 
result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, and 
IEC. I understand that they are publicly presented. 
7. I have understood that my identity will be kept confidential if my data are publicly presented 
8. I have had my questions answered to my satisfaction. 
9. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. By 
signing this consent form I attest that the information given in this document has been clearly 
explained to me and understood by me, I will be given a copy of this consent document. 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if participant 
incompetent) 
Name _________________________ Signature_________________ Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name _________________________ Signature_________________ Date________________ 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name _________________________ Signature_________________ Date________________ 
 
ANNEXURE 6  
Muha;r;rp xg;Gjy; fbjk ; 
Muha;r;rp jiyg;G: re;Njfj;jpw;Fhpa fhr Neha; jpRf;fspy; [Py; ePy;rd; 
epwkpiaAk; ,k;KNdh ;`p];Nlhnfkp];l;upiaAk; Xg;gpl;Lghh;f;Fk; 
Ma;T. 
nrd;id kUj;Jtf; fy;Y}hp Neha; Fwpapay; Jiwapy; gapYk; 
KJfiy kUj;Jth; F.tPuuhftd; mth;fs; Nkw;nfhs;Sk; ,e;j Ma;tpy; 
gq;Fnfhs;s .......................................................... Mfpa ehd; KOkdJld; 
rk;kjpf;fpNwd;. 
vdf;F tpsf;fg;gl;l tp\aq;fis ehd; Ghpe;Jf; nfhz;L vdJ 
rk;kjj;ij njhptpf;fpd;Nwd;. 
,e;j Muha;r;rpapy; gpwhpd; eph;ge;jkpd;wp vdJ nrhe;j 
tpUg;gj;jpd; Nghpy; jhd; gq;F ngWfpNwd; kw;Wk; ehd; ,e;j 
Muha;r;rpapy; ,Ue;J ve;NeuKk; gpd; thq;fyhk; vd;gijAk; ,jdhy; 
ve;j ghjpg;Gk; Vw;glhJ vd;gijAk; ehd; Ghpe;Jf; nfhz;Nld;.  
ehd; fhrNeha; Fwpj;j ,e;j Muha;r;rp tptuq;fis nfhz;l 
jfty; jhis ngw;Wf; nfhz;Nld;. 
ehd; vd;Dila RaepidTld; kw;Wk; KO Rje;jpuj;Jld; ,e;j 
kUj;Jt Muha;r;rpapy; vd;id Nrh;j;Jf; nfhs;s rk;kjpf;fpNwd;. 
vdf;F mWit rpfpr;ir nra;ag;gl;L Neha; Fwpapay; Jiwapy; 
rij ghpNrhjid gad;gl;l nkOFf;fl;bfis itj;J Muha;r;rp kw;Wk; 
rpwg;G ghpNrhjid nra;J nfhs;s rk;kjk; njhptpf;fpNwd;. 
 
gq;Nfw;ghsh; ifnahg;gk;............................. ,lk; : ........................ Njjp: ....................... 
gq;Nfw;ghsh; ngah; kw;Wk; tpyhrk; : 
Muha;r;rpahsh; ifnahg;gk; ........................ ,lk; : ......................... Njjp:...................... 
 
 
  
 
 
 
 
 
MASTER CHART 
 S. No Biopsy No. Age Sex HIV Status
Anti 
tuberculous 
therapy 
History
Clinical 
Suspicion 
of TB Site Necrosis
Immuno 
Histo 
chemistry
IHC 
Staining 
Intensity 
Score
Ziehl 
Neelsen 
Stain
1 7/16 44 M Negative Untreated No Ileum Present Positive 2 Negative
2 513/16 26 F Negative Untreated No Breast Absent Positive 3 Negative
3 540/16 24 F Negative Untreated No Lymph node Present Positive 2 Negative
4 1022/16 34 M Negative Untreated Yes Omentum Absent Positive 3 Positive
5 1434/16 36 M Negative Untreated Yes Lymph node Present Positive 3 Negative
6 1767/16 52 M Negative Untreated No Lymph node Present Positive 3 Negative
7 5814/16 23 M Negative Untreated No Bone marrow Absent Positive 2 Negative
8 5939/16 23 M Negative Untreated No Liver Absent Negative 0 Negative
9 6025/16 20 F Negative Untreated Yes Vertebra Absent Positive 3 Negative
10 7028/16 34 M Negative Untreated No Ileocecal Junction Absent Positive 3 Negative
11 7033/16 55 M Negative Untreated No Ileocecal Junction Absent Positive 3 Positive
12 7581/16 50 M Negative Untreated Yes Peritoneum Absent Positive 3 Negative
13 8015/16 19 M Negative Untreated No Soft Tissue Absent Positive 2 Negative
14 8109/16 55 M Negative Untreated No Lymph node Present Positive 3 Negative
15 8761/16 26 F Negative Treated Yes Vertebra Present Positive 3 Negative
16 8857/16 46 M Negative Untreated No Ileocecal Junction Absent Positive 3 Negative
17 9116/16 53 M Negative Untreated No Soft Tissue Present Positive 2 Negative
18 9235/16 60 M Negative Untreated No Peritoneum Present Positive 3 Negative
19 11537/16 25 M Negative Untreated No Lymph node Present Positive 3 Positive
20 11950/16 62 M Negative Untreated No Jejunum Absent Positive 2 Negative
21 12106/16 23 F Negative Untreated No Urinary Bladder Absent Negative 0 Negative
22 8/17 52 F Negative Untreated No Soft Tissue Absent Negative 0 Negative
23 257/17 28 F Negative Untreated Yes Lymph node Present Positive 3 Negative
24 295/17 20 M Negative Untreated Yes Lymph node Present Negative 1 Negative
25 327/17 26 M Negative Untreated No Lymph node Present Positive 3 Positive
26 358/17 34 M Negative Treated Yes Lymph node Absent Positive 3 Positive
27 452/17 22 F Negative Treated Yes Lymph node Present Positive 2 Negative
28 772/17 27 F Negative Untreated No Abscess Wall Present Positive 2 Negative
29 843/17 30 F Negative Untreated Yes Lymph node Present Positive 2 Negative
30 1162/17 23 M Negative Untreated No Lymph node Present Positive 3 Negative
31 1297/17 42 F Negative Treated Yes Soft Tissue Absent Positive 2 Negative
32 1507/17 36 F Negative Untreated Yes Lymph node Present Positive 3 Negative
33 1655/17 24 M Negative Untreated No Synovium Present Positive 3 Negative
34 1725/17 50 M Positive Untreated No Lymph node Present Positive 3 Negative
35 1870/17 50 M Negative Untreated No Ileum Absent Negative 1 Negative
36 1925/17 32 F Negative Untreated Yes Lymph node Present Positive 2 Negative
37 2159/17 29 M Negative Untreated No Lymph node Present Positive 2 Negative
38 2290/17 59 M Negative Untreated No Ileum Absent Positive 2 Negative
39 2414/17 30 F Negative Treated Yes Lymph node Absent Positive 2 Negative
40 2634/17 54 F Negative Untreated Yes Lymph node Absent Negative 1 Negative
41 2644/17 23 F Negative Untreated No Soft Tissue Absent Positive 2 Negative
42 2945/17 26 F Negative Untreated No Soft Tissue Absent Positive 3 Positive
43 3120/17 45 F Negative Untreated No Vertebra Absent Negative 0 Negative
44 3421/17 23 M Negative Untreated No Ileum Absent Negative 0 Negative
45 3660/17 16 F Negative Untreated No Lymph node Absent Positive 2 Negative
46 3678/17 25 M Negative Untreated No Lymph node Present Positive 2 Negative
47 3953/17 23 F Negative Untreated Yes Peritoneum Absent Negative 0 Negative
48 4083/17 36 F Negative Untreated No Lymph node Present Positive 3 Negative
49 4148/17 30 F Negative Untreated Yes Peritoneum Absent Positive 2 Negative
50 4222/17 23 F Negative Untreated No Lymph node Present Positive 2 Negative
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